UNITED ~~STATESSECURITIES~~STATES SECURITIES AND EXCHANGE ~~COMMISSIONWashington~~COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

~~[ ]~~¨ Form 20-F ~~[X]~~ x Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
	99.1	Condensed Interim Consolidated Three and nine months ended September 30, 2025
99.1		News Release dated November 5, 2025 - Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
	99.2	Management’s Discussion and Analysis Three and nine months ended September 30, 2025
	99.3	Form 52-109F2 Certification of Interim Filings - CEO
	99.4	Form 52-109F2 Certification of Interim Filings - CFO

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: November 5, 2025	By:	/s/ Chris Waddick
Date: November 13, 2025	By:	/s/ Chris Waddick
		Chris Waddick
		Name:	Chris Waddick
	~~Title:~~	~~Chief Financial Officer~~Title:	Chief Financial Officer

Filing Compare · Cardiol Therapeutics Inc.